retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Efficacy and safety of retatrutide, a GIP, GLP-1, and receptor agonist, in people with type diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Lilly orforglipron oral GLP-1 phase
Pay in 4 interest-free payments of $6.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5


























